Sequella to Present at 2006 ICAAC Conference

Sequella, Inc. 9610 Medical Center Drive Rockville, MD 20850 Tele: 301-762-7776 www.sequella.com NEWS RELEASE September 25, 2006 SEQUELLA TO PRESENT AT 2006 ICAAC CONFERENCE Three Sequella Scientists Selected By ICAAC Program Committee ROCKVILLE, MD, SEPTEMBER 25, 2006 – Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential announced today three Sequella scientists -- Dr. Boris Nikonenko, Dr. Elena Bogatcheva, and Mr. Francis Barbosa -- have been selected to present at the 46 th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Conference in San Francisco, California, on September 29 th . More than 12,000 physicians, researchers, and health care professionals from around the globe attend ICAAC, an educational exchange to foster worldwide solutions to address infectious diseases. Dr. Nikonenko is scheduled to present "Drug Therapy of Experimental TB: Improvement of Outcome by Substitution of SQ109 for Ethambutol in Three and Four Drug Regimens." The presentation will demonstrate that SQ109, Sequella’s lead clinical drug candidate, at a dose 10-fold lower than that of EMB, improved treatment of experimental TB in mice increasing efficacy of the standard drugs (by more than 1 log 10 ) and shortening treatment regimen time by at least 25%. Dr. Bogatcheva will present “Identification of a New Compound Series with Activity against Mycobacterium tuberculosis from a Diverse Combinatorial Library.” This session will cover the study of a diverse library of 14,438 compounds that have been synthesized and screened in vitro against M. tuberculosis . This research led to the discovery of a novel series of compounds structurally unrelated to any existing anti-tuberculosis drugs. Mr. Barbosa will present a poster abstract entitled, “In Vitro Antifungal Susceptibility Testing Of Drug Candidate SQ109 Against Candida Albicans.” The presentation will show that SQ109, when tested against a panel of organisms during pre-clinical assessment, also demonstrated significant activity against Candida albicans . For more information on Sequella visit, www.sequella.com . For more information on the ICAAC 46 th annual meeting, scheduled for September 27–30, 2006, visit www.icaac.org . ### About Sequella, Inc. Sequella is a clinical-stage biopharmaceutical company focused on commercializing improved treatment paradigms for diseases of epidemic potential. The company leverages its global influence, infectious disease expertise, and diverse product portfolio to proactively address emerging health threats with significant market opportunity. For more information, please visit www.sequella.com Forward-Looking Statement Sequella, Inc. 9610 Medical Center Drive Rockville, MD 20850 Tele: 301-762-7776 www.sequella.com This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law. MEDIA CONTACT: Alicia Moran Phone: 703-739-2424 x110.

The release as fetched from its publisher. sequella.com ↗